F10G2.1 Antibody

Here’s a structured FAQ collection for researchers studying the F10G2.1 Antibody (BLIMP-1 ortholog in C. elegans), based on experimental methodologies and findings from developmental biology studies:

Advanced Research Questions

• How does BLMP-1 degradation by DRE-1/FBXO11 influence experimental design for developmental timing studies?

  • Approach: Combine dre-1 mutants with tissue-specific promoters (e.g., lin-26p for epidermis) to express BLMP-1::GFP. Use cycloheximide chase assays to measure BLMP-1 half-life changes .

  • Critical finding: BLMP-1 accumulates in dre-1 mutants, leading to precocious seam cell differentiation (evidenced by alae formation in L4) .

• What contradictions arise when interpreting BLMP-1 antibody signals in genetic suppressor screens?

  • Conflict: RNAi suppression of blmp-1 rescues dre-1 epidermal defects but exacerbates gonadal migration delays .

  • Resolution: Use tissue-specific RNAi (e.g., rde-1 rescue in epidermis/gonad) to disentangle pleiotropic roles .

Table 1: BLMP-1 Antibody Performance in Genetic Backgrounds

Table 2: Key Genetic Interactions with blmp-1

Methodological Guidance

• How to resolve nonspecific bands in BLMP-1 Western blots?

  • Optimize lysis buffer (include 1% Triton-X + protease inhibitors) and use pre-adsorption with blmp-1 knockout lysate to block cross-reactivity .

• What controls are essential for BLMP-1 tissue-specific localization studies?

  • Include blmp-1 transcriptional reporters (e.g., blmp-1p::GFP) to distinguish transcriptional vs. post-translational regulation .